At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
LY2495655drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, in Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating LY2495655 for Advanced Cancer. Completed, enrolled 29 participants across 7 sites.
Detailed Summary
This study is a multicenter, open-label, dose-escalation phase 1 study of intravenous (IV) LY2495655 in participants with advanced cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2012
Primary CompletionNov 2012
Study CompletionJan 2016
TodayJul 2026
First PostedFeb 1, 2012
Enrollment StartJan 1, 2008
Primary CompletionNov 1, 2012
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 14.4 years ago
Interventions
LY2495655drug
administered intravenously